INCR InterCure
- 3.110
- -0.180-5.47%
InterCure News
InterCure Reports FY Results
Intercure Ltd. Files April SEC Report
Press Release: InterCure Announces FY2023 Results: Revenue of NIS 356 Million and Adjusted EBITDA of NIS 61 Million
InterCure Announces FY2023 Results: Revenue of NIS 356 million and Adjusted EBITDA of NIS 61 million -- Revenues during 2023 reached NIS 356 million, alongside an Adjusted EBITDA1 of NIS 61
323 drugs, hurry up! America is facing the biggest “drug shortage” in history...
The US now seems to be facing an unprecedented “drug shortage”...
Intercure Ltd. Submits SEC Compliance Report
Press Release: InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 Million and EBITDA of Over NIS 50 Million
InterCure Announces Preliminary Estimated 2023 Revenue of NIS 351 million and EBITDA of over NIS 50 million -- Revenues for H2 2023 were affected by damages caused by the terrorist attack o
InterCure Congratulates Germany on Cannabis Reform, Expanding Its Global Footprint
InterCure provides an update following recent Cannabis Reform in Germany Expects to launch its first products in Germany in the coming months The Company continues to closely watch developments surrounding
InterCure Advances Restoration of Israeli Site Amid Conflict
InterCure Restoring Facility Near Israel-Gaza Border
By Denny Jacob InterCure, which does business as Canndoc, has begun the process of restoring a facility near the Israel-Gaza border and that they are advancing according to its plans. The medical ca
InterCure Provides an Update Regarding Nir Oz Facility
NEW YORK, and HERZLIYA, Israel, Feb. 13, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel
InterCure Will Issue 1,755,000 to 1,845,000 Shrs of the Co to the Sellers, Depending on the Shr Price of the Co at the Time of Completion >INCR
InterCure Will Issue 1,755,000 to 1,845,000 Shrs of the Co to the Sellers, Depending on the Shr Price of the Co at the Time of Completion >INCR
InterCure Signs Definitive Agreement to Acquire Leon Cannabis Pharmacy Chain
NEW YORK, and HERZLIYA, Israel, Jan. 31, 2024 (GLOBE NEWSWIRE) -- InterCure Ltd. (NASDAQ:INCR) (TASE: INCR) (dba Canndoc) ("InterCure" or the "Company"), the leading medical cannabis company in Israel
WKEY, INCR and ZJYL Are Among Pre Market Gainers
Analysts' Opinions Are Mixed on These Healthcare Stocks: 60 Degrees Pharmaceuticals, Inc. (SXTP), Arcturus Therapeutics (ARCT) and Intercure (INCR)
InterCure Wins Cannolam Arbitration Proceeding; InterCure Holds 100% Of The Shares In Cannolam; Amount Owed Will Be Determined And Paid As Part Of A Full Separation Process
InterCure Wins Cannolam Arbitration Proceeding; InterCure Holds 100% Of The Shares In Cannolam; Amount Owed Will Be Determined And Paid As Part Of A Full Separation Process
InterCure Unable to Assess Damage to Southern Israel Site
By Ben Glickman InterCure, which does business as Canndoc, said it is unable to assess the damage to its facility near the Israel-Gaza border. The medical cannabis company said it had "high certaint
BTBT, SFT and BLRX Among Pre-market Losers
Canndoc Reports Record Revenue Amid Cannabis Market Turmoil
InterCure Ltd. (NASDAQ:INCR) (TASE: INCR), which is doing business as Canndoc, reported its financial and operating results on Thursday for the three and six months ended June 30, 2023, "The first hal
Intercure H1 EPS $0.03 Down From $0.17 YoY, Sales $57.20M Up From $50.05M YoY
Intercure (NASDAQ:INCR) reported quarterly earnings of $0.03 per share. This is a 82.35 percent decrease over earnings of $0.17 per share from the same period last year. The company reported $57.20 m
InterCure Reports 1H Results
Analysis
Price Target
No Data
